Rafal Dziadziuszko

List of Publications by Year
in descending order

173	11,068	44444	36203
papers	citations	50 h-index	101 g-index

176	176	176	12508
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Loss of STING expression is prognostic in nonâ€“small cell lung cancer. Journal of Surgical Oncology, 2022, 125, 1042-1052.	0.8	8
2	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical Cancer Research, 2022, 28, 1302-1312.	3.2	74
3	STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues. Journal of Thoracic Oncology, 2022, 17, 351-352.	0.5	1
4	Preâ€•and postâ€treatment bloodâ€based genomic landscape of patients with ROS1 or NTRK fusionâ€positive solid tumours treated with entrectinib. Molecular Oncology, 2022, 16, 2000-2014.	2.1	10
5	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Nonâ€“small Cell Lung Cancer in the Global Phase III ALEX Trial. Clinical Cancer Research, 2022, 28, 1800-1808.	3.2	26
6	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusionâ€“Positive NSCLC. JTO Clinical and Research Reports, 2022, 3, 100332.	0.6	15
7	Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).. Journal of Clinical Oncology, 2022, 40, LBA9023-LBA9023.	0.8	4
8	Quality of life (QoL) of OSE2101 in patients with HLA-A2+ nonâ€“small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial.. Journal of Clinical Oncology, 2022, 40, 9094-9094.	0.8	0
9	Role of radiotherapy in the management of brain metastases of NSCLC â€“ Decision criteria in clinical routine. Radiotherapy and Oncology, 2021, 154, 269-273.	0.3	11
10	Afatinib in EGFR TKI-naÃ¯ve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer, 2021, 152, 127-134.	0.9	17
11	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusionâ€“Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2021, 39, 1253-1263.	0.8	74
12	Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. Cancer Chemotherapy and Pharmacology, 2021, 88, 259-270.	1.1	11
13	Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).. Journal of Clinical Oncology, 2021, 39, 9023-9023.	0.8	0
14	Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-Î±, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.. Journal of Clinical Oncology, 2021, 39, 5510-5510.	0.8	14
15	Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse. Translational Lung Cancer Research, 2021, 10, 2452-2474.	1.3	11
16	Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. Journal of Thoracic Oncology, 2021, 16, 2040-2050.	0.5	26
17	Role of Postoperative Radiotherapy in the Management for Resected NSCLC â€“ Decision Criteria in Clinical Routine Pre- and Post-LungART. Clinical Lung Cancer, 2021, 22, 579-586.	1.1	9
18	Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score â‰¥2 â€“ Systematic review and meta-analysis. Lung Cancer, 2021, 158, 97-106.	0.9	31

#	Article	IF	Citations
19	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1647-1662.	0.5	274
20	Authorsâ€™ Reply to Role of Primary Prevention in Lung Cancer Control in Poland. Journal of Thoracic Oncology, 2021, 16, e94-e95.	0.5	0
21	366â€…Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial. , 2021, 9, A394-A394.		0
22	The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts. Radiotherapy and Oncology, 2020, 145, 45-48.	0.3	9
23	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 261-270.	5.1	303
24	ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. ESMO Open, 2020, 5, e000820.	2.0	96
25	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 631-640.	0.4	40
26	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 146, 223-229.	0.3	168
27	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. Radiotherapy and Oncology, 2020, 149, 84-88.	0.3	13
28	Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer â€“ Decision criteria in routine practise. Radiotherapy and Oncology, 2020, 150, 26-29.	0.3	13
29	Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.. Journal of Clinical Oncology, 2020, 38, 9518-9518.	0.8	18
30	Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncology, The, 2019, 20, 1702-1709.	5.1	88
31	Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?. Translational Lung Cancer Research, 2019, 8, 559-574.	1.3	5
32	Definition of Synchronous Oligometastatic Nonâ€“Small Cell Lung Cancerâ€”A Consensus Report. Journal of Thoracic Oncology, 2019, 14, 2109-2119.	0.5	189
33	Galectin-9 in non-small cell lung cancer. Lung Cancer, 2019, 136, 80-85.	0.9	32
34	OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Translational Lung Cancer Research, 2019, 8, 352-366.	1.3	38
35	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 133, 163-166.	0.3	24
36	A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. British Journal of Cancer, 2019, 121, 131-138.	2.9	16

#	Article	IF	Citations
37	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of Thoracic Oncology, 2019, 14, 1086-1094.	0.5	99
38	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of AlectinibÂinÂUntreated ALK-Positive Advanced Nonâ€“Small CellÂLung Cancer in the Global Phase III ALEX Study. Journal of Thoracic Oncology, 2019, 14, 1233-1243.	0.5	324
39	Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)â€“Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. Journal of Thoracic Oncology, 2019, 14, 1255-1265.	0.5	59
40	Increased plasma concentration of 4-pyridone-3-carboxamide-1-ÃŸ-D-ribonucleoside (4PYR) in lung cancer. Preliminary studies. Nucleosides, Nucleotides and Nucleic Acids, 2019, 38, 781-787.	0.4	4
41	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer, 2019, 131, 95-103.	0.9	40
42	Authorsâ€™ Reply. Journal of Thoracic Oncology, 2019, 14, e196-e197.	0.5	0
43	ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IBâ€“IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS8569-TPS8569.	0.8	39
44	ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2019, 37, TPS9121-TPS9121.	0.8	1
45	T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 895-906.	1.3	29
46	Can an Integrative SNP Approach Substitute Standard Identification in Comprehensive Case/Control Analyses?. Advances in Intelligent Systems and Computing, 2019, , 123-130.	0.5	0
47	Circulating free DNA as a prognostic biomarker in patients with advanced ALK+ NSCLC treated with alectinib from the global phase III ALEX trial.. Journal of Clinical Oncology, 2019, 37, 9053-9053.	0.8	2
48	Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 3334-3347.	3.2	182
49	Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Annals of Oncology, 2018, 29, 1409-1416.	0.6	238
50	Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey. Advances in Radiation Oncology, 2018, 3, 125-129.	0.6	9
51	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2018, 13, 413-425.	0.5	66
52	NSCLC molecular testing in Central and Eastern European countries. BMC Cancer, 2018, 18, 269.	1.1	28
53	STELLAR: Final results of a phase II trial of TTFields with chemotherapy for first-line treatment of pleural mesothelioma. Annals of Oncology, 2018, 29, viii641.	0.6	0
54	Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors. Cancer Treatment Reviews, 2018, 71, 59-67.	3.4	39

#	Article	IF	Citations
55	Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice. Cancer Treatment and Research Communications, 2018, 17, 18-22.	0.7	3
56	Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors. Kardiologia Polska, 2018, 76, 670-670.	0.3	1
57	LAG-3 Protein Expression in Nonâ€“Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 2017, 12, 814-823.	0.5	192
58	P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1. Journal of Thoracic Oncology, 2017, 12, S1085-S1086.	0.5	1
59	The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR -mutant NSCLC Patients. EORTC 1613. Clinical Lung Cancer, 2017, 18, 583-588.	1.1	84
60	Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland. Oncology Letters, 2017, 14, 5611-5618.	0.8	7
61	Serum lipid profile discriminates patients with early lung cancer from healthy controls. Lung Cancer, 2017, 112, 69-74.	0.9	57
62	MHC class II expression in lung cancer. Lung Cancer, 2017, 112, 75-80.	0.9	80
63	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 110-120.	0.5	108
64	Alectinib versus Crizotinib in Untreated ALK-Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 829-838.	13.9	1,858
65	Radiation dose to the left anterior descending coronary artery during interstitial pulsed-dose-rate brachytherapy used as a boost in breast cancer patients undergoing organ-sparing treatment. Journal of Contemporary Brachytherapy, 2017, 1, 7-13.	0.4	3
66	Osimertinib â€“ effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors. Wspolczesna Onkologia, 2017, 3, 254-258.	0.7	8
67	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Medical Science Monitor, 2017, 23, 1208-1216.	0.5	49
68	Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study. Acta Biochimica Polonica, 2017, 64, 513-518.	0.3	25
69	A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial.. Journal of Clinical Oncology, 2017, 35, 9070-9070.	0.8	21
70	Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. Journal of Clinical Oncology, 2017, 35, LBA9008-LBA9008.	0.8	6
71	Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. Journal of Clinical Oncology, 2017, 35, LBA9008-LBA9008.	0.8	16
72	An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number. Oncotarget, 2017, 8, 17270-17278.	0.8	3

#	Article	IF	Citations
73	Abstract 2626: Expression of human poliovirus receptor, an immune checkpoint biomarker in lung cancer. , 2017, , .		0
74	Pulsed-dose-rate peri-operative brachytherapy as an interstitial boost in organ-sparing treatment of breast cancer. Journal of Contemporary Brachytherapy, 2016, 6, 492-496.	0.4	1
75	Of mice and men: olfactory neuroblastoma among animals and humans. Veterinary and Comparative Oncology, 2016, 14, e70-82.	0.8	13
76	Serum mass profile signature as a biomarker of early lung cancer. Lung Cancer, 2016, 99, 46-52.	0.9	25
77	An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1273-1281.	0.5	71
78	Whole Brain Radiotherapy for Patients with Nonâ€“Small Cell Lung Cancer with EGFR Mutationsâ€”Why and When?. Journal of Thoracic Oncology, 2016, 11, 1604-1605.	0.5	2
79	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. ESMO Open, 2016, 1, e000118.	2.0	6
80	Abstract 3190: Genomic profiling of salivary gland tumors identifies novel and targetable alterations. Cancer Research, 2016, 76, 3190-3190.	0.4	1
81	LAG 3/MHC 2 and PD 1/PD L1 expression in non-small cell lung cancer patients.. Journal of Clinical Oncology, 2016, 34, 3039-3039.	0.8	4
82	Detection of actionable genome alterations using hybrid capture based next generation sequencing technology: NEOplus and NEOliquid.. Journal of Clinical Oncology, 2016, 34, e23181-e23181.	0.8	0
83	Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1083-1090.	0.5	30
84	Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe. Journal of Thoracic Oncology, 2015, 10, 1370-1374.	0.5	25
85	Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage Iâ€“III Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1067-1075.	0.5	15
86	CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab. Molecular Diagnosis and Therapy, 2015, 19, 79-89.	1.6	8
87	LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. British Journal of Radiology, 2015, 88, 20150036.	1.0	96
88	Rociletinib in EGFR-Mutated Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 1700-1709.	13.9	615
89	The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology, 2015, 141, 61-68.	1.2	32
90	Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. Journal of Clinical Oncology, 2015, 33, 992-999.	0.8	326

#	Article	IF	Citations
91	Stereotactic body radiotherapy for central lung tumours:Author reply. British Journal of Radiology, 2015, 88, 20150532.	1.0	0
92	Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.. Journal of Clinical Oncology, 2015, 33, 8063-8063.	0.8	19
93	Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget, 2015, 6, 5182-5194.	0.8	72
94	Abstract 927: Pretreatment and serial plasma assessments of EGFR mutations in NSCLC patients treated with rociletinib (CO-1686). , 2015, , .		1
95	THORACIC SURGERY Early results of a trimodality treatment for superior sulcus tumors. Kardiochirurgia I Torakochirurgia Polska, 2014, 3, 268-272.	0.1	0
96	FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. Clinical Cancer Research, 2014, 20, 3299-3309.	3.2	141
97	Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study. Journal of Thoracic Oncology, 2014, 9, 1354-1362.	0.5	34
98	Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treatment Reviews, 2014, 40, 716-722.	3.4	123
99	Miliary Brain Metastases in a Patient with ROS1-Rearranged Lung Adenocarcinoma: A Case Report. Journal of Thoracic Oncology, 2014, 9, e34-e36.	0.5	17
100	Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience.. Journal of Clinical Oncology, 2014, 32, 11035-11035.	0.8	4
101	Abstract 921: Fibroblast growth factor receptor 1 (FGFR1) protein expression and gene copy number in small cell lung cancer. , 2014, , .		0
102	Abstract 5587: Serial monitoring ofEGFRmutations in plasma and evaluation ofEGFRmutation status in matched tissue and plasma from NSCLC patients treated with CO-1686. , 2014, , .		0
103	EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?. Lancet Oncology, The, 2013, 14, 916-917.	5.1	12
104	Pulsed dose rate brachytherapy of lip cancer. Journal of Contemporary Brachytherapy, 2013, 3, 144-147.	0.4	10
105	Beneath the Blood Brain Barrier: The Challenge of Diagnosis and Management of Central Nervous System Involvement in ALK-Positive Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1465-1466.	0.5	4
106	Abstract B25: Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686.. Molecular Cancer Therapeutics, 2013, 12, B25-B25.	1.9	5
107	A lack of correlation between mast cells, angiogenesis, and outcome in non-small cell lung cancer. Experimental Lung Research, 2012, 38, 281-285.	0.5	9
108	Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 982-992.	0.5	15

#	Article	IF	Citations
109	Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 340-347.	0.5	147
110	Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Research, 2012, 14, R119.	2.2	87
111	Continuous 7-Days-A-Week External Beam Irradiation in Locally Advanced Cervical Cancer: Final Results of the Phase I/II Study. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1256-1261.	0.4	0
112	Radiotherapy and targeted drugs. Lung Cancer, 2012, 77, S2.	0.9	0
113	Randomized Clinical Trials Using New Technologies in Radiation Oncology: Ethical Dilemma for Medicine and Science. Journal of Thoracic Oncology, 2012, 7, 3-4.	0.5	1
114	Insulin-like growth factor 1 (IGF-1R) protein expression (PE) and gene copy number (GCN) for discrimination of response and outcome to figitumumab in NSCLC.. Journal of Clinical Oncology, 2012, 30, 7597-7597.	0.8	1
115	Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiotherapy and Oncology, 2011, 100, 76-85.	0.3	142
116	MicroRNA in lung cancer diagnostics and treatment. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 717, 25-31.	0.4	52
117	Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer. Clinical Cancer Research, 2011, 17, 5257-5267.	3.2	75
118	Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. British Journal of Cancer, 2011, 105, 1-8.	2.9	52
119	A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 3567-3573.	0.8	77
120	Abstract 5136: Discovery of novel functional germline variations in the vascular endothelial growth factor receptor 2 gene (KDR) and their effect on gene expression and microvessel density in lung cancer. , 2011, , .		0
121	Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment: Results of a Randomized Phase II Study. Journal of Thoracic Oncology, 2010, 5, 1255-1262.	0.5	25
122	Increased Insulin-Like Growth Factor 1 Receptor Protein Expression and Gene Copy Number in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1905-1911.	0.5	50
123	Insulin-like Growth Factor Receptor 1 (IGF1R) Gene Copy Number Is Associated With Survival in Operable Nonâ€“Small-Cell Lung Cancer: A Comparison Between IGF1R Fluorescent In Situ Hybridization, Protein Expression, and mRNA Expression. Journal of Clinical Oncology, 2010, 28, 2174-2180.	0.8	116
124	Quantitative immunohistochemistry in lung cancer: clinical perspective.. Folia Histochemica Et Cytobiologica, 2010, 48, 7-11.	0.6	6
125	ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Annals of Oncology, 2009, 20, 689-695.	0.6	37
126	Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Research and Treatment, 2009, 117, 297-303.	1.1	45

#	Article	IF	Citations
127	The Rationale and Development of Therapeutic Insulin-like Growth Factor Axis Inhibition for Lung and Other Cancers. Clinical Lung Cancer, 2009, 10, 262-272.	1.1	25
128	Abstract B45: Analysis ofcâ€¥Metgene copy number by dualâ€¢color silverin situhybridization (SISH) in nonâ€¢small cell lung cancer (NSCLC). , 2009, , .		1
129	Epidermal growth factor receptor immunohistochemistry. Cancer, 2008, 112, 1114-1121.	2.0	69
130	Advances in Genomic and Proteomic Studies of Nonâ€“Small-Cell Lung Cancer: Clinical and Translational Research Perspective. Clinical Lung Cancer, 2008, 9, 78-84.	1.1	20
131	Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 6317-6323.	3.2	63
132	Exacerbation of diabetes related to exemestane treatment. Acta OncolÃ³gica, 2008, 47, 1167-1169.	0.8	2
133	The Insulin-Like Growth Factor Pathway in Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 815-818.	0.5	78
134	First-Generation Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer: Clinical Impact of the Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Assay. Journal of Thoracic Oncology, 2008, 3, S138-S142.	0.5	10
135	Mass Spectrometry to Classify Nonâ€“Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study. Journal of the National Cancer Institute, 2007, 99, 838-846.	3.0	303
136	Primary Malignant Fibrous Histiocytoma of the Lung. Thoracic and Cardiovascular Surgeon, 2007, 55, 186-189.	0.4	13
137	Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Annals of Oncology, 2007, 18, 447-452.	0.6	41
138	M03-04: Selecting lung cancer patients to targeted therapies based on protein expression by immunohistochemistry. Journal of Thoracic Oncology, 2007, 2, S157-S158.	0.5	1
139	D2-05: Biomarker analysis of the TRIBUTE Trial of chemotherapy with or without erlotinib in advanced non-small cell lung cancer (NSCLC): FISH positivity predicts outcome. Journal of Thoracic Oncology, 2007, 2, S395.	0.5	0
140	PL2-02: Molecular staging of lung cancer. Journal of Thoracic Oncology, 2007, 2, S143-S144.	0.5	2
141	Unusual Chemosensitivity of Advanced Bronchioalveolar Carcinoma after Gefitinib Response and Progression: A Case Report. Journal of Thoracic Oncology, 2007, 2, 91-92.	0.5	3
142	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2007, 18, 752-760.	0.6	257
143	Two autologous transplants in the treatment of patients with Hodgkin's lymphoma: Analysis of prognostic factors and comparison with a single procedure. Leukemia and Lymphoma, 2007, 48, 535-541.	0.6	9
144	M06-03: Prediction of benefit from EGFR TKIs by proteomic analysis of pretreatment serum. Journal of Thoracic Oncology, 2007, 2, S167-S168.	0.5	0

#	Article	IF	Citations
145	Epidermal Growth Factor Receptor Targeted Therapyâ€"Markers of Sensitivity and Response. Translational Medicine Series, 2007, , 97-122.	0.0	0
146	PD2-3-6: ERBB3 expression correlates with vorinostat and gefitinib activity and its co-expression with E-cadherin restores response to gefitinib in NSCLC. Journal of Thoracic Oncology, 2007, 2, S445-S446.	0.5	0
147	Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report. Journal of Thoracic Oncology, 2007, 2, 91-2.	0.5	3
148	Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 5034-5042.	0.8	701
149	Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer, 2006, 52, 9-14.	0.9	45
150	Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines. Cancer Research, 2006, 66, 944-950.	0.4	482
151	Intraoperative, Radio-Guided Sentinel Lymph Node Mapping in 110 Nonsmall Cell Lung Cancer Patients. Annals of Thoracic Surgery, 2006, 82, 237-242.	0.7	52
152	Blue-dye intraoperative sentinel lymph node mapping in early non-small cell lung cancer. European Journal of Surgical Oncology, 2006, 32, 462-465.	0.5	23
153	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 740-743.	0.5	2
154	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 740-743.	0.5	5
155	Chemotherapy with mitomycin c, ifosfamide, and cisplatin for recurrent or persistent cervical cancer. International Journal of Gynecological Cancer, 2006, 16, 1152-1156.	1.2	5
156	Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer. Biomarkers, 2006, 11, 262-269.	0.9	5
157	Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 3078-3084.	3.2	97
158	Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridizationâ€"Why, When, and How?. Clinical Cancer Research, 2006, 12, 4409s-4415s.	3.2	52
159	Biological Markers for Nonâ€"Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. Clinical Cancer Research, 2006, 12, 3652-3656.	3.2	62
160	Lung Function in Patients Operated for Chronic Pleural Empyema. Thoracic and Cardiovascular Surgeon, 2005, 53, 245-249.	0.4	9
161	A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC). British Journal of Cancer, 2005, 92, 1038-1045.	2.9	80
162	Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Annals of Oncology, 2004, 15, 1222-1230.	0.6	46

#	Article	IF	Citations
163	P53and K-rasmutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. Cancer, 2004, 100, 1951-1960.	2.0	20
164	MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer, 2004, 43, 285-295.	0.9	58
165	The influence of blood transfusion on survival in operated nonâ€“small cell lung cancer patients. Journal of Thoracic and Cardiovascular Surgery, 2003, 126, 755-760.	0.4	24
166	Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. European Journal of Cancer, 2003, 39, 1271-1276.	1.3	107
167	Decortication in chronic pleural empyema â€" effect on lung function. European Journal of Cardio-thoracic Surgery, 2002, 21, 502-507.	0.6	50
168	Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancerâ€“Lung Cancer Group Phase III Trialâ€"08923. Journal of Clinical Oncology, 2002, 20, 3947-3955.	0.8	102
169	High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplantation, 2002, 30, 29-34.	1.3	18
170	Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance. Lung Cancer, 2001, 31, 17-23.	0.9	17
171	Results of surgical treatment of nonâ€“small cell lung cancer: validation of the new postoperative pathologic tnm classification. Journal of Thoracic and Cardiovascular Surgery, 2000, 119, 1141-1146.	0.4	62
172	Clinical implications of molecular abnormalities in lung cancer. Cancer Treatment Reviews, 1998, 24, 317-330.	3.4	9
173	Interleukin 12 Augments Natural Killer-Cell Mediated Cytotoxicity in Hairy Cell Leukemia. Leukemia and Lymphoma, 1993, 10, 121-125.	0.6	13